University Hospital Tuebingen: Melanoma trials
The registry lists 15 Melanoma studies with University Hospital Tuebingen as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 10Phase 3 1No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young AdultsRecruitingNCT06680323
- Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaTerminatedNCT03728465Phase 2
- Early Therapy Response Monitoring in Melanoma Patients Using PET/MRIStatus unknownNCT03132090Not applicable
- Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)Status unknownNCT02452294Phase 2
- Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)CompletedNCT02434107Not applicable
- FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA)CompletedNCT02425475
- Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTerminatedNCT02303951Phase 2
- Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb StudyTerminatedNCT02052193Phase 2
- A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2CompletedNCT01480323Phase 2
- NAM-Trial: Multiferon in Malignant MelanomaCompletedNCT01341158Phase 2
- Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma PatientsCompletedNCT00204607Phase 1/2
- Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28CompletedNCT00204594Phase 1/2
- Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma MetastasesCompletedNCT00204581Phase 2
- Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIBCompletedNCT00204529Phase 3
- Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted AntigensCompletedNCT00204516Phase 1/2